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Transcriptional and Functional Analyses of SLC12A3 Mutations:
New Clues for the Pathogenesis of Gitelman Syndrome
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Gitelman syndrome (GS) is a recessive salt-losing tubulopathy that is caused by mutations in the SLC12A3 gene that encodes
the sodium-chloride co-transporter (NCC). GS is characterized by significant inter- and intrafamilial phenotype variability,
with early onset and/or severe clinical manifestations in some patients. No correlations between the disease variability and the
position/nature of SLC12A3 mutations have been investigated thus far. In this study, extensive mutational analyses of
SLC12A3 were performed in 27 patients with GS, including genomic DNA sequencing, multiplex ligation-dependent probe
amplification, cDNA analysis, and quantification of allele-specific transcripts, in parallel with functional analyses in Xenopus
laevis oocytes and detailed phenotyping. Twenty-six SLC12A3 mutations were identified in 25 patients with GS, including
eight novel (detection rate 80%). Transcript analysis demonstrated that splicing mutations of SLC12A3 lead to frameshifted
mRNA subject to degradation by nonsense-mediated decay. Heterologous expression documented a novel class of NCC
mutants with defective intrinsic transport activity. A subgroup of patients presented with early onset, growth retardation,
and/or detrimental manifestations, confirming the potential severity of GS. The mutations that were associated with a severe
presentation were the combination at least for one allele of a missplicing resulting in a truncated transcript that was
downregulated by nonsense-mediated decay or a nonfunctional, cell surface–absent mutant. The most recurrent mutation on
the second allele was a newly described NCC mutant that affected the functional properties of the co-transporter. These data
suggest that the nature/position of SLC12A3 mutation, combined with male gender, is a determinant factor in the severity of
GS and provide new insights in the underlying pathogenic mechanisms of the disease.
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G itelman’s syndrome (GS; MIM #263800) is an autoso-mal recessive salt-losing renal tubulopathy that ischaracterized by hypomagnesemia, hypocalciuria,
and secondary aldosteronism that is responsible for hypokale-
mia and metabolic alkalosis. The prevalence of heterozygotes is
approximately 1% in European populations (1), making it the
most frequent inherited tubulopathy. The disease is due to loss
of function mutations in the SLC12A3 gene (16q13) that codes
for the thiazide-sensitive NaCl co-transporter (NCC) (2–10).
NCC is a 1021–amino acid integral membrane protein that is
expressed mainly in the epithelial cells of the renal distal con-
voluted tubule (DCT), where it is responsible for the reabsorp-
tion of 5 to 10% of filtered Na and Cl (11). Loss-of-function
mutations of NCC explain the clinical manifestations of GS,
which are similar to the prolonged administration of thiazide
diuretics (12).
To date, more than 100 mutations scattered throughout the
SLC12A3 gene have been identified in GS (Human Gene Mu-
tation Database [HGMD], http://www.hgmd.cf.ac.uk). The
majority of mutations are missense substitutions, but nonsense,
frameshift, and splice-site (ss) defects and gene rearrangements
have also been described. Classically, GS has been considered
as a benign variant of salt-losing nephropathies, with most
cases being diagnosed during adolescence or adulthood in
routine evaluation, often asymptomatic or mild (13–16). How-
ever, clinical studies have revealed that patients with GS show
a considerable phenotypic variability not only among patients
who carry a wide variety of SLC12A3 mutations (5) but also
when a common underlying mutation is present in unrelated
patients (17) and even in affected patients from the same family
(18–20). A limited number of patients may show an early onset,
severe neuromuscular manifestations (e.g., tetany, seizures,
rhabdomyolysis), growth retardation, chondrocalcinosis, and
ventricular arrhythmia (5,21,22). Even if genetic background
and environmental effects may influence disease severity, one
may hypothesize that the extent to which a given SLC12A3
mutation modifies the NCC co-transporter activity is crucial.
Thus far, the molecular basis of the phenotype variability in GS
remains unknown. Functional analysis has been performed
only for a limited number of mutations, without phenotypic
counterpart, and the potential correlations between the posi-
tion/nature of mutation in SLC12A3, the mutation-determined
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transcriptional profile, and the clinical manifestations have not
been addressed.
In this study, we investigated the mutational spectrum for
SLC12A3 in 27 patients who received a clinical and biochemical
diagnosis of GS. For all single base substitutions at or close to ss
consensus sequence, the effect on the pre-mRNA splicing was
confirmed by cDNA analyses, and the proportion of the differ-
ent transcripts that were generated by these mutations was
analyzed. We documented a significant phenotype heterogene-
ity among the 25 patients who harbored SLC12A3 mutations,
including a subgroup of nine patients with early-onset and
severe manifestations. We further characterized biochemically
and structurally a panel of missense mutants in Xenopus laevis
oocytes and delineated their association with phenotypic infor-
mation. These data provide the first evidence to suggest that
the potential severity of GS is related to a combination of the
nature and the functional consequence of the SLC12A3 muta-
tions with male gender. They also give new insights into the
functional domains of NCC and the underlying pathogenic
mechanisms of GS.
Materials and Methods
Patient Recruitment and Clinical Evaluation
Twenty-seven patients who had a diagnosis of GS from 23 noncon-
sanguineous Belgian families were recruited through the Belgian Net-
work for the Study of Gitelman Syndrome. All patients met the classical
diagnostic criteria for GS (5,21,23). The patients were documented for
renal and extrarenal phenotypic manifestations, and routine parame-
ters were recorded at time of diagnosis. The patients with GS were
classified as “severe” when they had at least two of the following
criteria: Early onset of the disease, before age 12; growth delay (height
below the third percentile, or height velocity below the tenth percentile)
and/or final short stature (below the third percentile); detrimental
neuromuscular symptoms (e.g., repeated episodes of palsy, hypotonia,
tetany, detrimental cramps, blurred vision); cardiac arrhythmia related
to prolonged QT; and symptomatic chondrocalcinosis. The ethical com-
mittee of the Université Catholique de Louvain Medical School ap-
proved the present study, and informed consent was obtained from
participants and/or their parents.
Screening for Mutations in SLC12A3
Total DNA was extracted from blood peripheral leukocytes (Gentra
Systems Puregene, Minneapolis, MN). Twenty-six primer pairs were de-
signed to amplify by PCR the coding region and flanking intronic se-
quences of SCL12A3 gene (Supplementary Table 1). Thirty cycles of PCR
were performed in the presence of 1.5 l of 25 mMMgCl2 using AmpliTaq
Gold (Perkin Elmer Applied Biosystems, Foster City, CA). The PCR prod-
ucts were directly sequencedwith the BigDye terminator kit (Perkin Elmer
Applied Biosystems). Sequence reactions were purified with MultiScreen
SEQ384 Filter Plate (Millipore, Billerica, MA) and Sephadex G-50 DNA
Grade Fine (Amersham Biosciences, Piscataway, NJ) dye terminator re-
moval, before analysis on ABI3100 capillary sequencer (Perkin Elmer
Applied Biosystems). Ss predictions were performed using Automated
Splice Site Analyses (http://splice.cmh.edu) (24).
Multiplex Ligation–Dependent Probe Amplification Analysis
A specifically designed SALSA multiplex ligation–dependent probe
amplification (MLPA) P136 SLC12A3 kit (MRC-Holland, Amsterdam, The
Netherlands) was used for the screening. The P136 probe mix included
probes for 25 of the 26 exons of the SLC12A3 gene, as well as 13 control
probes for sequences located in other genes. Amplification products were
identified on an ABI 3100 capillary sequencer using Genescan-ROX 500
standards and GeneMapper 4.0 software (Applied Biosystems). DNA
samples from healthy individuals were used as negative controls.
RNA Extraction and Reverse Transcriptase–PCR Analysis
of Allele-Specific Transcript Levels
To analyze transcriptional profiles and the potential influence of
mRNA nonsense-mediated decay (NMD) for the SLC12A3-splicing mu-
tations, we extracted total RNA from blood using Ficoll (Amersham)-
TRIZOL (Invitrogen, Carlsbad, CA). After DNAase treatment, RNA
was purified with Total RNA Purification System (Invitrogen) and
reverse-transcribed with Superscript III (Invitrogen). After the detec-
tion of a substitution at or close to a splice consensus sequence, several
exonic pairs of primers were designed to amplify cDNA regions that
comprised exons 6 to 8, 11 to 13, 13 to 17, 21 to 23, and 23 to 25. One
primer of each pair was used to sequence the PCR product. For quan-
tification of the allele representation of each reverse transcriptase–PCR,
1 l of reaction mixture mixed with 5 l of the loading buffer that
contained size markers (50 and 10,380 bp) was analyzed by capillary
electrophoresis in Agilent 2100 Bioanalyzer with DNA 7500 LabChip
(Agilent Technologies, Palo Alto, CA), under conditions of enabled
translation and active NMD. The Bioanalyzer 2100 software was used
to perform automated peak identification and determination of the
peak area of each cDNA fragment.
Functional Studies of SLC12A3 Mutations
Six mutations were selected for functional characterization (R145C,
N611S, G316V, R399C, A588V, and S555L), on the basis of their pres-
ence in heterozygosis in patients with a severe phenotype, their loca-
tion within the middle hydrophobic domain of NCC (thought to de-
termine the ion translocation and diuretic-binding specificity of the
co-transporter), and/or their recurrence in patients with GS.
NCC-Directed Mutagenesis. Wild-type NCC human cDNA was
cloned into pT7TS Xenopus laevis oocyte expression vector. The cDNA
was cloned into BgIII and SpeI sites between the 5 and 3 untranslated
regions of Xenopus -globin gene. A FLAG epitope tag was added at the
5 site of NCC to facilitate detection. Site-directed mutagenesis
(QuikChange Site-Directed Mutagenesis Kit; Stratagene, La Jolla, CA)
was performed following the manufacturer’s instructions. Direct se-
quencing of the full-length cDNA was performed to confirm mutagen-
esis. The six mutant constructs were linearized with EcoRI, and cRNA
transcripts were synthesized in vitro using T7 RNA polymerase (Pro-
mega, Madison, WI). Concentration of the cRNA was measured with a
spectrophotometer, and the integrity was confirmed by RNA formal-
dehyde-agarose gel electrophoresis.
Expression Studies in Xenopus laevis Oocytes. Oocytes were iso-
lated from Xenopus laevis and defolliculated by digestion at room temper-
ature for 2 h with 2 mg/ml collagenase A (Boehringer Mannheim, Mann-
heim, Germany) as described (7). Injection of 10 ng of wild-type or mutant
human NCC (hNCC) cRNA was performed 24 h after isolation. Immuno-
blotting, 22Na uptake assay, and immunocytochemistry were performed
2 d after injection as described previously (7). Isolation of total and plasma
membranes was performed in 15 oocytes per condition. Protein samples
were immunoblotted onto polyvinylidene difluoride membranes and suc-
cessively incubated with 1:8000 dilution mouse anti-FLAG (Sigma, St.
Louis,MO) and 1:2000 diluted sheep horseradish peroxidase conjugated to
anti-mouse IgG (Sigma) antibodies, before visualization by enhanced
chemiluminescence (Pierce, Havertown, PA). Twenty-four hours before
the 22Na uptake assay, 15 oocytes per condition were transferred to a Cl
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free medium and next transferred to 500 l of uptake medium that
contained 1 Ci/ml 22Na for 2 h at room temperature. Ouabain and
bumetanide were added to block the Na-K-ATPase and the Na-K-
2Cl co-transporter, respectively. Amiloride was added to block the
Na-H antiporter and Na channels. Next, washing in ice-cold uptake
mediumwas performed five times to stop the uptake reaction. Each oocyte
was solubilized in 200 l of 10% (wt/vol) SDS, and radioactivity was
counted in a liquid scintillation counter. For immunocytochemistry, the
remaining vitellinemembranewas removed 2 d after oocyte injection. Five
to 10 peeled oocytes per condition were fixed at room temperature during
2 h in 1% (wt/vol) paraformaldehyde fixative, dehydrated, and paraf-
fined. Seven-micrometer-thick sections were cut and incubated overnight
at 4°C with mouse anti-FLAG antibody (Sigma) diluted 1:200 followed by
incubation at room temperature for 1 h with goat Alexa 488–conjugated
anti-mouse IgG (Invitrogen, Eugene, OR) diluted 1:250.
Statistical Analyses
Results are expressed as means  SEM. Comparisons between
groups were made by unpaired t test or Fisher exact test as appropriate.
The significance level was set at P  0.05.
Results
Mutation Screening
Sequence analysis of the SLC12A3 gene of 23 probands (27
patients including four siblings) with a clinical diagnosis of GS
revealed 26 different punctual mutations, including eight
novel. These mutations include 22 missense, three ss, and one
duplication (Table 1). All mutations co-segregated with the
phenotype and were not detected in 220 control chromosomes.
The novel variants are six missense mutations (R145C, S350L,
Table 1. Mutations in SLC12A3 identified in the 25 patients with GSa
Location Nucleotide Changeb Predicted Effect onCoding Sequencec
No. of
Patients Reference
Missense
ex 3 c.433CT R145C 1 This study
ex 4 c.514TC W172R 2 Syren et al., 2002 (6)
ex 5 c.644TC L215P 1 Lemmink et al., 1998 (4)
ex 7 c.947GT G316V 1 Syren et al., 2002 (6)
ex 8 c.1049CT S350L 1 This study
ex 10 c.1195CT R399C 4 Cruz et al., 2001 (5)
ex 12 c.1452CG C484W 1 This study
ex 12 c.1456GA D486N 1 Simon et al., 1996 (2)
ex 12 c.1567GA A523T, p.Cys482_Ala523LeufsX6 1 This study
ex 13 c.1664CT S555L 3 Cruz et al., 2001 (5)
ex 14 c.1763CT A588V 1 Simon et al., 1996 (2)
ex 15 c.1832AG N611S 1 This study
ex 15 c.1868TC L623P 1 Takeuchi et al., 1996 (3)
ex 15 c.1925GA R642H 1 Lemmink et al., 1998 (4)
ex 16 c.1964GA R655H 1 Simon et al., 1996 (2)
ex 18 c.2186GC G729V 1 Cruz et al., 2001 (5)
ex 18 c.2221GA G741R 4 Simon et al., 1996 (2)
ex 22 c.2554GA R852C 1 Lemmink et al., 1998 (4)
ex 24 c.2755CT R919C 1 Lemmink et al., 1998 (4)
ex 25 c.2903GA R968Q 1 This study
Splice site
ex 26 c.2938GA G980R 1 De Jong et al., 2002 (7)
ex 26 c.2954GA C985Y 1 Syren et al., 2002 (6)
IVS7 c.9641GT ex 7 skip. p.Ala285_Ala322ArgfsX48 1 This study
IVS22 c.26331GC ex 22 skip. p.Gly841_Ala878GlyfsX6 1 Godefroid et al., 2006 (8)
Duplication
IVS24 c.28561GT ex 24 skip. p.His907_Lys952HisfsX6 2 Simon et al., 1996 (2)
ex 23 c.2667dupA p.Phe890IlefsX3 1 This study
aCompound heterozygous, mild: c.514TC1925GA (female), c.644TC1049CT (female),
c0.947GT2667dupA (female), c.1664CT1452CG (female), c.1195CT2954GA (female),
c.1195CT1832AG (female), c.1456GA1868TC (female), c.1964GA2221GA (female),
c.2186GC2554GA (female), c.28561GT2938GA (female); compound heterozygous, severe:
c.433CT9641GT (male), c.514TC2221GA (male), c.1664CT2221GA (male), c.1763CT1567GA
(male), c.1664CT26331GC (female); simple heterozygous, mild: c.2903GA? (female), c.1195CT? (male),
c.2221GA? (male), c.2755CT? (male); simple heterozygous, severe: c.1195CT? (male), c.28561GT?
(male). No homozygous patients were identified. ex, exon; GS, Gitelman syndrome.
bThe numbering of nucleotide starts at the first adenine of the translation initiation codon.
cThe numbering of amino acids starts at the first methionine encoded by the translation initiation codon.
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C484W, A523T, N611S, and R968Q) that substitute strongly
conserved amino acids (data not shown); a ss mutation
(c.9641GT) and a duplication of an adenine (c.2667dupA)
that caused a frameshift that resulted in a stop codon at posi-
tion 3 in exon 23 (p.Phe890IlefsX3; Figure 1). Heterozygosity
was observed for all SLC12A3 mutations that were detected in
this study. Two mutant alleles were detected in 15 affected
individuals, whereas only one was identified in six individuals,
and no mutation was identified in the remaining two patients
(Table 1). MLPA was performed in the six patients who had GS
and in whom only one mutant allele was found and in the two
without detectable mutation. No alteration in the copy number
of the 26 exons of SLC12A3 could be detected in any of the eight
samples (data not shown).
The mutations were distributed throughout the SLC12A3
gene with the exception of exons 1, 2, 6, 9, 11, 17, and 19 to 21.
Figure 1. Novel SLC12A3 mutations identified in patients with Gitelman syndrome (GS). Direct sequencing of PCR fragments of
different exons for novel sodium-chloride co-transporter (NCC) mutations in control subjects (Ct) and patients with GS (Pt). The
encoded amino acid sequence is indicated in three-letter format above the DNA sequence. Mutated bases are indicated above the
normal base. Intronic bases are shown in lower case. For nomenclature, the numbering of nucleotide starts at the first adenine of
the translation initiation codon.
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Exons 12 and 15 were the most frequent sites of mutation (six
[23%] of 26 mutations). The most common mutations that
caused GS were two missense, R399C and G741R (allele fre-
quency eight [approximately 17%] of 46; Table 1). The missense
S555L is the third recurrent mutation, with an allele frequency
of approximately 6%, and was found in three patients. All other
mutations were identified in only one or two patients.
Analysis of Splicing Mutations
DNA analysis revealed three different point mutations that
occurred in the invariant motif of the 5 donor ss: c.26331GC,
c.28561GT, and the novel c.9641GT (Table 1). Two mis-
sense mutations, A523T and R642H, that resulted from guanine-
to-adenine transitions at the last nucleotide upstream of the 5
donor ss of exons 12 and 15, respectively, were also predicted to
affect the splicing. Using Automated Splice Site Analyses (24),
mutations that affected the consensus 5donor ss in intron 7
(c.9641GT), intron 22 (c.26331GC), and intron 24
(c.28561GT) were predicted to abolish the splicing (	Ri 7.8,
	Ri 12.8, 	Ri 7.8), whereas both missense A523T and R642H
were predicted to affect splicingwithout activation of a cryptic site
(	Ri 3.1).
Reverse Transcriptase–PCR and cDNA Sequencing. cDNA
sequencing was performed to confirm the splicing predictions
(Figure 2). The cDNA from the two siblings who carried the het-
erozygous c.9641GT yielded no full-length product but a shorter
transcript characterized by skipping of exon 7. At the protein level,
this change resulted in a new reading frame that ended in a stop
codon at position 48 in exon 9 (p.Ala285_Ala322ArgfsX48). Anal-
ysis of the sibling patients who carried the mutation c.1567GA
revealed an aberrantly spliced transcript that lacked exon 12, in
addition to correctly spliced transcript with the predicted mis-
sense mutation, A523T. This skipping resulted in a frameshift and
the introduction of a stop codon at position 6 of exon 13
(p.Cys482_Ala523LeufsX6). Analysis of the patient who carried
the mutation c.1925GA revealed the presence of one aberrant
splice transcript that contained an insertion of a 104-bp intronic
Figure 2. Schematic overview of SLC12A3 and representation of abnormal splicing in patients with GS. The structure of SLC12A3
and its 26 exons is shown on top. Dotted boxes enclose the abnormally assembled exons after RNA splicing. For nomenclature,
the numbering of nucleotide starts at the first adenine of the translation initiation codon; numbering of amino acids starts at the
first methionine encoded by the translation initiation codon. Consequences of five splicing mutations on the RNA splicing are
illustrated. For each mutation, a scheme that includes the correct splice transcript and the aberrant product(s) is shown. Triangles
mark the mutated residues; mutant threonine at position 523 and histidine at position 642 are also indicated.
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sequence between exon 15 and exon 16 (r.1926_1926ins104bp),
responsible for a new reading frame that ended in a stop codon at
position 2 (p.Arg642ArgfsX2). In addition, a correctly spliced tran-
script with the predicted missense R642H was observed. The
presence of the splicing mutation c.26331GC in one patient
caused the occurrence of an abnormal transcript that lacked the
entire exon 22 in addition to the normal-length transcript. As a
consequence, a new reading frame that ended in a stop codon at
position 6 in exon 23 was created (p.Gly841_Ala878GlyfsX6).
Analysis of the cDNA from two patients who carried
c.28561GT showed the skipping of the entire exon 24 in the
abnormally spliced transcript with the introduction of a stop
codon as result of the frameshift at position 6 of exon 25
(p.His907_Lys952HisfsX6).
Relative Quantification of Mutant Transcript Levels. To
assess whether NMD operates for truncated mutant SLC12A3
transcripts, we determined the percentage of expression of each
aberrantly spliced transcript versus the correctly spliced product
(taken as 100%). The expression of frameshifted transcripts was
significantly reduced when compared with the correctly spliced
products: 58 and 46% for the two siblings who carried the
c.9641GT mutation; 13% for both siblings with c.1567GA;
53% for c.26331GC; 32% for the patient who carried the mu-
tation c.1925GA; and 9 and 13%, respectively, for the two pa-
tients from two different families with c.28561GTmutation. Of
note, the proportions were homogeneous among the five truncat-
ing mutations for which transcript levels could be assessed in
more than one patient. These results suggest that NMD is trig-
gered by the incorrectly spliced products of SLC12A3.
Phenotype Analysis
On the basis of their clinical features, the 25 patients who
harbored mutations in SLC12A3 were classified either in a
severe (at least two criteria of severity) or mild (classical GS
features, no criteria of severity) subgroup (Table 2). There were
eight male patients for only one female patient in the severe
subgroup. In contrast, there were 13 female patients among the
16 patients in the mild subgroup. Most of the severe patients
(eight of nine, including seven males and one female) had
growth delay and low height velocity, with catchup growth
observed after initiation of substitutive treatment (Figure 3,
Supplementary Table 2), confirming our earlier observation in
the female patient (8). All adolescent patients showed pubertal
delay (Supplementary Table 2), and three of them had final
short stature. Six patients experienced severe, detrimental neu-
romuscular manifestations (hypotonia, palsy, tetany, and se-
vere cramps). Two patients had repeated episodes of blurred
vision, and one presented a picture of idiopathic intracranial
hypertension that could be related to secondary aldosteronism
(8). One patient experienced a cardiac arrest in childhood re-
lated to prolonged QT. Of note, four patients in this group
received a misdiagnosis of Bartter’s syndrome before mutation
analysis. There were two pairs of male siblings among the
severe group (c.[433CT][9641GT] and c.[1763CT]
[1567GA]), with a similar presentation in terms of age and
clinical manifestations. By contrast, patient c.[1664CT]
[2221GA], who presented with severe chondrocalcinosis and
detrimental neuromuscular manifestations, had one affected
but asymptomatic sister who presented only a mild hypokale-
mia that was detected during a routine screening. In addition to
the difference in gender ratio and age at presentation, patients
who were in the severe group had lower diastolic BP and
urinary calcium excretion and a trend for lower plasma K
levels and higher urine Na/K ratio (Table 2).
Functional Studies in Xenopus Oocytes
The expression and glycosylation profile of six selected mu-
tants was investigated in Xenopus oocytes, which do not exhibit
endogenous thiazide-sensitive NCC (25). Total membrane ex-
tracts from oocytes that expressed wild-type NCC revealed two
bands that corresponded to the core (110 kD) and complex
glycosylated (130 to 140 kD) isoforms of NCC, respectively
Table 2. Clinical and laboratory parameters in the two subgroups of patients who had GS and harbored SLC12A3
mutationsa
Parameter
Subgroup of Patients with GS
P
Severe (n 
 9) Mild (n 
 16)
Gender ratio 1 F/8 M 13 F/3 M 0.002
Systolic BP (mmHg) 101 3 108 6 NS
Diastolic BP (mmHg) 56 3 70  4 0.02
pNa (mEq/L; NV 135 to 145) 138 0.6 138 0.5 NS
pK (mEq/L; NV 3.5 to 5) 2.4 0.2 2.6 0.1 NS
pHCO3
 (mEq/L; NV 22 to 29) 31.5 0.9 31.7 0.8 NS
pMg2 (mEq/L; NV 1.45 to 1.9) 1.3 0.1 1.2 0.1 NS
uNa (mEq/L) 135 18 97  14 0.13
uK (mEq/L) 76 14 61 7.0 NS
uNa/K 2.8 0.7 1.7 0.2 0.08
uCa2/creatinine (mg/mg; NV 0.15) 0.033 0.005 0.070 0.016 0.05
aF, female; M, male; NV, normal value; p, plasma; u, urine.
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(Figure 4B, top). A similar pattern was observed in oocytes that
expressed the mutants R145C, A588V, S555L, and N611S,
whereas the 110-kD band was detected only in mutants G316V
and R399C. Immunoblotting of plasma membrane extracts
showed the presence of mutants R145C, A588V, S555L, and
N611S at the cell surface, with variable level of expression as
compared with wild-type. In contrast, G316V and R399C mu-
tants were not detected in the plasma membrane fraction (Fig-
ure 4B, bottom).
The functionality of mutant NCC co-transporters was inves-
tigated using thiazide-sensitive 22Na uptake. The G316V,
R399C, S555L, and A588V mutants showed the same level of
activity as noninjected oocytes, whereas mutants R145C and
N611S showed a rate of 22Na uptake of 35 and 53%, respec-
tively, compared with oocytes that expressed the wild-type
protein (Figure 4C). Immunocytochemistry confirmed the re-
sults that were obtained by immunoblotting of the plasma
membrane extracts (Figure 4D). Antibodies against FLAG-
Figure 3. Growth curves of the male patients with GS in the severe subgroup. The seven male patients in the severe subgroup
showed a significant growth delay at different ages. Catchup growth was observed after initiation of K and Mg2 supplements
(arrows) in three of them. A color code was assigned for each patient, with ID assigned in Table 3.
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epitope demonstrated typical plasma membrane staining in
oocytes that expressed wild-type hNCC. By contrast, intracel-
lular staining was observed exclusively in oocytes that ex-
pressed nonfunctional mutants such as G316V, whereas func-
tional mutants such as N611S showed positive staining at both
the plasma membrane and the cytoplasm. The mutants S555L
and A588V, which did not exhibit a significant level of 22Na
uptake, showed a positive intracellular and plasma membrane
staining. These results indicate that among the six mutations
tested, G316V and R399C are not complex glycosylated, absent
from the plasma membrane, and nonfunctional. The mutants
R145C and N611S exhibit complex glycosylation, presence in
both the plasma membrane and the cytoplasm, and an inter-
mediate level of activity compared with wild-type. The remain-
ing mutants S555L and A588V show complex glycosylation and
presence in both cell surface and cytoplasm, contrasting with a
lack of intrinsic activity and thereby representing a novel class
of NCC mutants that were not previously identified in GS.
Genotype–Phenotype Correlations
On the basis of the clinical, genetic, molecular, and functional
data described, we investigated potential genotype–phenotype
correlations in this cohort of patients with GS. When consider-
ing the nine patients who harbored a severe phenotype, we
noticed that six of them carried a splice mutation that led to a
truncated NCC transcript that was downregulated by NMD
(Figure 2, Table 3). The prevalence of splicing mutations in the
severe GS subgroup was significantly higher than in the clas-
sical, mild GS subgroup (six of nine versus two of 16, respec-
tively; P  0.01) and in the HGMD database (10 of 113; P 

0.0001). Five of these patients were compound heterozygous for
the splice defect and a missense mutation that affected either
Figure 4. Functional studies of missense mutations in SLC12A3. (A) Position of the selected mutations in the predicted topology
of human NCC (hNCC). Glycosylation sites are shown as branches. The localization of each mutation is represented by a triangle.
(B) Immunoblots of total membrane (top) and plasma membrane (bottom) extracts that were isolated from Xenopus oocytes, either
noninjected (NI) or injected with 10 ng of wild-type (WT) or mutant hNCC cRNA. (C) 22Na uptake in oocytes that expressed WT
or mutant hNCC. Uptake values are shown as percentage of the WT, where 100% represents an uptake of 22.5 pmol/oocyte per
2 h. **P  0.05, ***P  0.0001 in relation to the uptake of NI oocytes. (D) Representative immunocytochemistry of oocytes injected
with WT or mutant hNCC: Plasma membrane staining in an oocyte injected with WT hNCC (a); NI oocyte with only background
staining (b); oocyte expressing nonfunctional G316V mutant with intracellular staining only (a similar pattern was observed for
R399C; c); oocyte injected with functional N611S mutation that presented both plasma membrane and intracellular staining (a
similar pattern was found for R145C; d); nonfunctional S555L-expressing oocyte showing both plasma membrane and intracellular
staining (a similar pattern was observed for A588V; e).
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ion transport activity (S555L, A588V) or routing to the cell
surface of a functional mutation (R145C) rather than resulting
in a direct impact on the glycosylation. Only one mutant allele
(c.28561GT) was found in the remaining patient. The re-
maining three patients with a severe phenotype were male and
had at least a nonfunctional mutant, absent from the cell surface
(G741R and R399C) in one allele. The most recurrent mutation
on the second allele among the group of severely affected
patients was a newly described NCC mutant, suggesting a
defect in the intrinsic activity of the co-transporter. No patient
who carried a functional mutation in both alleles was identified
in the severe subgroup. Of note, the two splicing mutations that
were detected in the mild subgroup were present in female
patients, as were six of eight nonfunctional, plasma membrane–
absent mutants. Only two male patients in the mild subgroup
harbored this kind of nonfunctional mutant, and the second
mutation could not be detected in these patients. Taken to-
gether, these results suggest that the nature of the mutations of
SLC12A3, combined with male gender, is a determinant factor
for explaining a severe phenotype in patients with GS.
Discussion
In this study, a total of 26 different mutations in the SLC12A3
gene (including eight novel) were identified in a series of 25
patients with GS, including 22 missenses, three ss, and one
duplication. All of the missense mutations substitute amino
acids that are strongly conserved through evolution. Five mu-
tations that were predicted to alter the normal RNA splicing
were confirmed by cDNA analysis. Analysis of the transcrip-
tion profiles demonstrated that all of the splicing mutations
trigger NMD. Functional characterization of missense muta-
tions demonstrated the existence of a novel class of NCC mu-
tants, characterized by a lack of intrinsic activity despite normal
glycosylation and plasma membrane expression. A high prev-
alence of splicing mutations were detected in the subgroup of
patients who harbored a severe phenotype. Although limited
by the relatively small number of severe cases, these data
suggest that the combination of male gender with the presence
of one allele of a splice defect that results in a truncated tran-
script or, less frequently, a nonfunctional intracellularly re-
tained mutation could explain the clinical severity of GS.
Table 3. Clinical presentation, genotype, functional defect, and splice products in the nine severely affected
patients
Genotype (Class of Functional Defect)b
Gender ID Age atOnset Phenotype at Presentation Allele 1 Allele 2
Aberrant
Splice
Productsc
(%)
M GS01.1 10 yr Growth and pubertal delay,
severe hypotonia, weakness,
dysesthesia
c.9641GT (Ex 7 skip.
p.Ala285_Ala322ArgfsX48)
c.433CT, p.(R145C)
Defective insertion,
functional
58
M GS01.2 9 yr Growth and pubertal delay,
asthenia, convulsion with
cardiac arrest, prolonged QT
c.9641GT (Ex 7 skip.
p.Ala285_Ala322ArgfsX48)
c.433CT, p.(R145C)
Defective insertion,
functional
46
F GS02.1 12 yr Growth delay, short stature,
cramps, dysesthesia, tetany,
pseudotumor cerebri
c.26331GC (Ex 22 skip.
p.Gly841_Ala878GlyfsX6)
c.1664CT, p.(S555L)
Defective intrinsic
activity
53
M GS03.1 17.5 yr Growth and pubertal delay,
invalidating cramps,
dysesthesia, nocturia, major salt
craving
c.1567GA (A523T,
p.Cys482_Ala523LeufsX6)
c.1763CT, p.(A588V)
Defective intrinsic
activity
13
M GS03.2 16 yr Growth and pubertal delay,
nocturia, repeated cramps and
dysesthesia
c.1567GA (A523T,
p.Cys482_Ala523LeufsX6)
c.1763CT, p.(A588V)
Defective intrinsic
activity
13
M GS04.1 9 yr Growth delay, severe episodes of
tetany and palsy, cramps,
asthenia, polyuria, nocturia
c.28561GT (Ex 24 skip.
p.His907_Lys952HisfsX6)
? 13
M GS05.1 21 yr Severe neuromuscular symptoms,
chondrocalcinosis, profound
hypomagnesemia, tetany,
paralysis
c.2221GA, p.(G741R)
Defective processing, non-
functionald
c.1664CT, p.(S555L)
Defective intrinsic
activity
ND
M GS06.1 21 mo Growth delay, hypotonia c.2221GA, p.(G741R)
Defective processing, non-
functionald
c.514TC,
p.(W172R)ND
ND
M GS07.1 18 mo Growth and pubertal delay,
hypotonia, dysesthesia
c.1195CT, p.(R399C) Defective
processing, non-functional
? ND
aND, not determined (for missense mutations); ?, unidentified mutation at the second allele.
bBased on Sabath et al. (31).
cRelative quantification as percentage of the correct splice product from the other allele.
dFunctional studies by de Jong et al. (7).
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The mutation detection rate is this series of patients with GS
is approximately 80%. Only one mutant allele has been identi-
fied in affected individuals from six families (26%), compatible
with the 40% of simple heterozygosity previously reported (26).
Among them, four were patients who presented in adulthood
with mild symptoms but all of the classic biologic manifesta-
tions of GS, indicating that they are indeed affected by GS and
not only carriers. The GS is recessively inherited, with simple
heterozygous relatives being clinically and metabolically
asymptomatic, although increased urinary sodium excretion
reflecting higher sodium intake has been mentioned in one
study that investigated a large Amish kindred (27). The high
proportion of single heterozygosity among affected patients is
likely due to a failure to identify the mutation in the other allele.
Furthermore, mutations were not detected in two patients who
met the classical diagnosis criteria of GS. Explanations for this
detection failure include large genomic rearrangements or mu-
tations in regulatory fragments or deeper intronic sequences
that are not routinely screened. Alternatively, the expression of
the NCC co-transporter may be influenced by epigenetic mod-
ifications and/or silent polymorphisms that could interfere
with its function. Also, other genes that code for functionally
related channels or transporters that are located in the distal
nephron may be involved (26). The possibility of large deletions
in our series was excluded by using MLPA (28), because no
difference in the copy numbers of the 26 target exons was
detected in the six simple heterozygous and the two patients
who were negative for the mutation screening.
The majority (22 [85%] of 26) of mutations that were detected
in this series are missense, as described previously (4,6). Fewer
than one third of the mutations that are associated with GS and
collected in the HGMD include nonsense, frameshift, and ss
defects and gene rearrangements that are likely to have a
loss-of-function effect on the co-transporter. These changes pre-
dict premature translation stop codons with likely loss through
the mRNA surveillance pathway, NMD, which allows cells to
degrade mRNA that contain premature translation stop codons
if they are located at a position more than 50 to 54 nucleotides
upstream of a splicing-generated exon–exon junction (29). We
provide the first evidence that SLC12A3 splice defects that lead
to frameshifted mRNA trigger the NMD process. The prefer-
ential degradation of each aberrantly spliced product has been
documented, with mutant transcript levels ranging from 9 to
58% compared with the normal transcript, supporting that
NMD operates with variable efficiency (30). The demonstration
that the NMD surveillance mechanism operates on SLC12A3
splice mutations suggests the residual translation of mutated
mRNA that will lead to truncated co-transporters. In turn, these
abnormal transcripts could partially explain disease variability
(Table 4).
Functional studies of mutant channels/transporters in the
Xenopus laevis oocyte heterologous expression system have sug-
gested that at least five different mechanisms can account for
the reduced or abolished transport activity: (i) impaired protein
synthesis; (ii) impaired protein processing to the cell surface;
(iii) impaired insertion of an otherwise functional protein into
the plasma membrane; (iv) impaired functional properties, with
defective intrinsic activity; and (v) accelerating protein removal
or degradation (31,32). De Jong et al. (7) investigated eight
mutant hNCC cDNA and distinguished two different classes of
mutations: Improperly glycosylated proteins retained in the
cytosol and normally glycosylated, functional mutants that are
partly impaired in their routing to the cell surface, which sug-
gested that the NCC processing defect represents the underly-
ing mechanism in GS.
We used the Xenopus heterologous expression system to in-
vestigate in detail six mutations that were detected in severely
affected patients and/or clustering on residues within the cen-
tral hydrophobic domain of NCC. On the basis of the glycosyl-
ation pattern, plasma membrane expression, and 22Na uptake,
we identified a novel class of NCC mutation that is exemplified
by A588V and S555L (Figure 4). These mutants are fully glyco-
sylated and expressed in the plasma membrane, with partial
retention inside the cell. However, they do not show intrinsic
activity when present at the plasma membrane. This reduced
activity is not due to defective protein synthesis, because the
total expression level of all mutant proteins was similar to
wild-type NCC expression. Therefore, our results suggest that
A588V and S555L belong to a novel class of NCC mutants that
affect the functional properties of the co-transporters. Of note,
Sabath et al. (31) recently investigated the functional properties
of the mouse A585V cDNA, which corresponds to the patho-
genic human mutation A588V identified here. They showed
that A585V generates a mutant protein that exhibits mature
glycosylation bands but an activity that represents only approx-
imately 6% of the wild type. In that work, 25 ng of cRNA was
Table 4. Different types of pathogenic mechanisms among the carriers of SLC12A3 mutations
Pathogenic Mechanisma SLC12A3 Mutations
Missplicing resulting in a truncated transcript
downregulated by nonsense-mediated decay;
impaired protein synthesis
c.9641GT, A523T, c.28561GT, c.2667dupA, R642H,
c.26331GC
Defective protein processing, no functionality G316V, R399C, G741Rb
Defective protein insertion, functionality R145C, L215Pb, N611S, G980Rb, C985Yb
Defective intrinsic activity S555L, A588V
aBased on Sabath et al. (31).
bMissense mutations previously studied by de Jong et al. (7).
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injected (versus 10 ng injected in our study), and the Km values
to assess the affinity of the mutant A585V for ions Na and Cl
were too low to be detectable. We therefore can presume that
mouse A585V, corresponding to human A588V, is indeed a
nonfunctional mutation, likely the result of a defect on its
intrinsic activity rather of a processing defect. The remaining
four mutations that were investigated here belong to previ-
ously described nonfunctional (G316V and R399C) and partly
functional (R145C and N611S) types of mutants.
Our results extend the range of pathogenic mechanisms that
underline GS by identifying NCC mutations that result in a
defective intrinsic transport activity, a mechanism that has not
been shown before to underline GS (Table 4). This pathogenic
mechanism is not exclusive for NCC mutations. Recent studies
have identified mutations that functionally impair other mem-
bers of the electroneural co-transporter family, such as
SLC12A1 and SLC12A6, without affecting their targeting to the
plasma membrane (33,34). Similarly, some mutations in the CF
gene alter the conduction of the Cl channel CFTR, without
affecting its targeting (35). Of note, most of these peculiar CF
mutations are located within the membrane-spanning domains
of CFTR (36,37), and both mutations that were identified here
are located within the central hydrophobic domain of NCC:
S555L lies at the end of TM10, whereas A588V is within TM12.
It has been suggested that the central domain of NCC deter-
mines ion translocation and thiazide-binding specificity (38,39),
which could provide a basis for the pathogenic role of these
missense mutations.
The transcriptional and functional analyses of SLC12A3 mu-
tations, combined with clinical characterization, give new in-
sights into the disease variability in GS. In agreement with
reports that suggested that GS is more severe than generally
anticipated (5,21,22), our series identified a subgroup of nine
patients with a severe phenotype including childhood presen-
tation, growth delay and/or pubertal delay, and severe clinical
manifestations. Although this subgroup was relatively small,
the phenotype was remarkably consistent (Table 3, Figure 3,
Supplementary Table 2). Comparison between these severe
cases and the more classical cases (Table 2) revealed significant
differences in BP control and extent of hypocalciuria, as well as
a trend for lower kalemia and increased urinary Na. Striking,
there were eight male patients for only one female patient in the
severe subgroup, whereas an inverse gender ratio was found in
the mild subgroup. These data confirm and extend previous
studies that reported that female patients with GS show milder
symptoms than do male patients (40), which could be explained
by a positive effect of estrogens. Several lines of evidence have
shown that estrogens affect a variety of mediators in renal
tissues (e.g., by stimulating the transcription and/or activity of
nitric oxide synthase isoforms, interacting with components of
the renin-angiotensin system [41]). In turn, such estrogen-me-
diated mechanisms could play a role in the association of male
gender with faster progression in various types of renal disease
(42). Furthermore, estrogens seem to have a direct effect on the
expression of NCC and the structure of the DCT: In ovariecto-
mized rats, estradiol replacement restored DCT ultrastructure
and NCC expression in the apical membrane of the tubule (43).
Of note, such a positive effect could also affect prepubertal
children, which is important when considering that five pa-
tients in the severe group had a prepubertal onset (age 10 yr).
Highly sensitive assays have detected very low concentrations
of estradiol in children before puberty, with significantly lower
levels (between three- and eight-fold) being observed in pre-
pubertal boys compared with girls at the same age (44). These
data suggest that the hypothalamic-pituitary-gonadal axis is
functionally active and plays a biologic role during childhood,
with children being extremely sensitive to sex steroid actions
(45). One therefore could speculate that the lower levels of
estradiol in prepubertal boys could play a role in the severe
phenotype that is associated with some mutations of NCC,
whereas a higher level of estrogens in prepubertal girls might
be sufficient to attenuate the manifestations.
Mutation analysis also yielded important information. The
SLC12A3 mutations that were associated with a severe presen-
tation in this cohort were at least the combination for one allele
of a missense mutation that resulted in a nonfunctional intra-
cellular retained protein or, even more frequent, a missplicing
that resulted in a short transcript that was downregulated by
NMD. Such splicing defects were detected in two third of the
severely affected patients, whereas their prevalence in the gen-
eral population of patients with GS is10%. It must be noted that
the phenotype of heterozygotes who carry relatively NMD-
resistant transcripts (40 to 60%) does not seem to be more severe
than in patients who carry sensitive NMD transcripts (15%).
This seeming lack of dominant negative effect may reflect the
inefficiency with which frameshifted mRNA are effectively trans-
lated. When we turn on the second allele of the patients with a
severe phenotype, the more recurrent mutation was the novel
NCC mutant, affecting the intrinsic functional properties of the
co-transporter. Taken together, these data suggest that the na-
ture/position of the harbored SLC12A3 mutation, combined
with male gender, can explain the clinical severity in a subset
of patients with GS. Accordingly, a remarkably similar pheno-
type was noted in two pairs of severely affected male siblings
(c.[433CT][9641GT] and c.[1763CT][1567GA]),
whereas a clinical discrepancy was observed between one se-
verely affected brother (c.[1664CT][2221GA]) and his sister,
who presented a much milder phenotype. The gender effect may
also explain why a female patient who is compound heterozygous
for a truncated mutation and a nonfunctional, intracellularly re-
tained substitution (c.[2667dupA][947GT])—predicted to be
severe—had a mild clinical and biochemical presentation.
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